Education
About Us
Working with TipRanks
Follow Us
Allergy Therapeutics PLC (GB:AGY)
LSE:AGY
Total Valuation
Allergy Therapeutics has a market cap or net worth of £706.27M. The enterprise value is 426.23M.
Market Cap£706.27M
Enterprise Value426.23M
Share Statistics
Allergy Therapeutics has 6,141,440,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding6,141,440,000
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Allergy Therapeutics’s return on equity (ROE) is 1.42 and return on invested capital (ROIC) is -69.33%.
Return on Equity (ROE)1.42
Return on Assets (ROA)-0.59
Return on Invested Capital (ROIC)-69.33%
Return on Capital Employed (ROCE)-0.73
Revenue Per Employee89.94K
Profits Per Employee-64.05K
Employee Count612
Asset Turnover0.81
Inventory Turnover2.15
Valuation Ratios
The current PE Ratio of Allergy Therapeutics is ―. Allergy Therapeutics’s PEG ratio is 0.44.
PE Ratio―
PS Ratio6.88
PB Ratio-13.44
Price to Fair Value-13.44
Price to FCF-11.85
Price to Operating Cash Flow-19.59
PEG Ratio0.44
Income Statement
In the last 12 months, Allergy Therapeutics had revenue of 55.04M and earned -40.13M in profits. Earnings per share was -0.01.
Revenue55.04M
Gross Profit25.13M
Operating Income-29.50M
Pretax Income-40.44M
Net Income-40.13M
EBITDA-29.43M
Earnings Per Share (EPS)-0.01
Cash Flow
In the last 12 months, operating cash flow was -28.72M and capital expenditures -3.26M, giving a free cash flow of -31.98M billion.
Operating Cash Flow-28.72M
Free Cash Flow-31.98M
Free Cash Flow per Share>-0.01
Dividends & Yields
Allergy Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.63
52-Week Price Change82.54%
50-Day Moving Average9.22
200-Day Moving Average7.93
Relative Strength Index (RSI)69.95
Average Volume (3m)460.33K
Important Dates
Allergy Therapeutics upcoming earnings date is Feb 26, 2026, TBA (Confirmed).
Last Earnings DateDec 11, 2025
Next Earnings DateFeb 26, 2026
Ex-Dividend Date―
Financial Position
Allergy Therapeutics as a current ratio of 1.28, with Debt / Equity ratio of -213.13%
Current Ratio1.28
Quick Ratio0.76
Debt to Market Cap0.14
Net Debt to EBITDA-1.61
Interest Coverage Ratio-4.31
Taxes
In the past 12 months, Allergy Therapeutics has paid -312.00K in taxes.
Income Tax-312.00K
Effective Tax Rate<0.01
Enterprise Valuation
Allergy Therapeutics EV to EBITDA ratio is -14.48, with an EV/FCF ratio of -13.33.
EV to Sales7.74
EV to EBITDA-14.48
EV to Free Cash Flow-13.33
EV to Operating Cash Flow-14.84
Balance Sheet
Allergy Therapeutics has £12.79M in cash and marketable securities with £60.09M in debt, giving a net cash position of -£47.30M billion.
Cash & Marketable Securities£12.79M
Total Debt£60.09M
Net Cash-£47.30M
Net Cash Per Share>-£0.01
Tangible Book Value Per Share>-£0.01
Margins
Gross margin is 45.65%, with operating margin of -53.60%, and net profit margin of -72.91%.
Gross Margin45.65%
Operating Margin-53.60%
Pretax Margin-73.48%
Net Profit Margin-72.91%
EBITDA Margin-53.46%
EBIT Margin-61.04%
Analyst Forecast
The average price target for Allergy Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-0.28%
EPS Growth Forecast22.94%